Literature DB >> 2439335

Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.

C Vincent, M Marceau, P Blangarin, P Bouic, J J Madjar, J P Revillard.   

Abstract

alpha 1-Microglobulin (alpha 1m) was determined by radio-immunoassay in the supernatants of five human hepatoma cell lines. High amounts of alpha 1m were produced by PLC/PRF/5, intermediate ones by Hep G2 and Hep 3B and very low ones by Malhavu and SK Hepl. alpha 1m isolated from hepatoma cell lines PLC/PRF/5 or Hep G2 supernatants displayed the same physicochemical properties as that purified from human urines: the apparent molecular mass was 26 kDa and the pI from 5.6 to 6.4 as measured after two-dimensional polyacrylamide gel electrophoresis in denaturating conditions; for the native molecule the pI was estimated to be 4.0-4.9. Both urinary and hepatoma alpha 1m migrate as a diffuse band in the alpha zone in agarose gel at pH 8.6 in non-denaturing conditions and present a brown chromophore covalently associated with the molecule. After biosynthetic labelling with [35S]methionine, proteins extracted from hepatoma cell line PLC/PRF/5 and from isolated hepatocytes of human liver were separated by two-dimensional PAGE and transferred to a nitrocellulose membrane. alpha 1m was identified and found to be identical in both cases. However, when compared with the alpha 1m isolated from cell supernatants, less charge heterogeneity but also minor additional spots of higher molecular mass were observed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439335     DOI: 10.1111/j.1432-1033.1987.tb11497.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

1.  Vitreous levels of oxidative stress biomarkers and the radical-scavenger α1-microglobulin/A1M in human rhegmatogenous retinal detachment.

Authors:  Martin Cederlund; Fredrik Ghosh; Karin Arnér; Sten Andréasson; Bo Akerström
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-25       Impact factor: 3.117

2.  Human inter-alpha-trypsin inhibitor. Synthesis and maturation in hepatoma HepG2 cells.

Authors:  J Bourguignon; R Sesboüé; M Diarra-Mehrpour; M Daveau; J P Martin
Journal:  Biochem J       Date:  1989-07-01       Impact factor: 3.857

3.  Evidence of tubular damage in the very early stage of chronic kidney disease of uncertain etiology in the North Central Province of Sri Lanka: a cross-sectional study.

Authors:  Shanika Nanayakkara; S T M L D Senevirathna; Upul Karunaratne; Rohana Chandrajith; Kouji H Harada; Toshiaki Hitomi; Takao Watanabe; Tilak Abeysekera; T N C Aturaliya; Akio Koizumi
Journal:  Environ Health Prev Med       Date:  2011-06-28       Impact factor: 3.674

4.  Alpha 1-microglobulin, beta 2-microglobulin and retinol binding protein in childhood febrile illness and renal disease.

Authors:  M D Donaldson; R E Chambers; M W Woolridge; J T Whicher
Journal:  Pediatr Nephrol       Date:  1990-07       Impact factor: 3.714

5.  Serum alpha 1-microglobulin and beta 2-microglobulin for the estimation of fetal glomerular renal function.

Authors:  S Nolte; B Mueller; W Pringsheim
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

6.  Up-regulation of A1M/α1-microglobulin in skin by heme and reactive oxygen species gives protection from oxidative damage.

Authors:  Magnus G Olsson; Maria Allhorn; Jörgen Larsson; Martin Cederlund; Katarina Lundqvist; Artur Schmidtchen; Ole E Sørensen; Matthias Mörgelin; Bo Akerström
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

7.  Alpha 1-microglobulin (HC protein) in human hepatocellular carcinoma.

Authors:  C Vincent; M C Kew; P Bouic; M Flacher; J P Revillard
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

8.  High-Risk Indicators of Renal Involvement in Primary Sjogren's Syndrome: A Clinical Study of 1002 Cases.

Authors:  Jing Luo; Yu-Wei Huo; Jian-Wu Wang; Hui Guo
Journal:  J Immunol Res       Date:  2019-02-17       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.